Drugs / Levocetrizine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT04324918 Comparator | Oct 2018 → Jun 2019 | perennial allergic rhinitis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT02551536 Comparator | Apr 2014 → Apr 2015 | allergic rhinitis | Indira Gandhi Medical College, Shimla | Completed | No outcome recorded |
| — | NCT07365683 Comparator | Aug 2025 → Jan 2026 | chronic idiopathic urticaria | Derma Techno Pakistan | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levocetrizine | “The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.” NCT04324918 ↗ |
| Known as | HGP1408 | “The participants will receive tretment of HGP1408(Levocetrizine), orally, once daily for 4weeks.” NCT04324918 ↗ |
| Known as | levocitrizine | “patients received tab bilastine 20 mg in the morning and tab levocitrizine 5 mg in the evening for 6 weeks” NCT07365683 ↗ |
| Action | Inhibit | “Levocetirizine, a potent second generation histamine (H1) receptor antagonist, is effective against persistent allergic rhinitis” NCT02551536 ↗ |
| Route | Oral | “group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D” NCT02551536 ↗ |